Webinar: Steps through the sand: stories from the Retina UK Sahara Trek
Join us for our upcoming webinar
Search
Search results
RP Awareness Month – Paul’s Story
During RP awareness month, Paul Bacon has shared how his diagnosis has impacted his life and shared messages about how non visually impaired people can support those living with inherited sight loss. To learn more about inherited sight loss please take the time to read Paul's story.
‘Talking’ Books Peer Support Group
Thursday 5 March 2026, 7.00pm - 8.00pm - via Zoom - To celebrate World Book Day we invite you to join us for our launch meeting and welcome group facilitators Cindy Peacock and Jane Copsey who both share a passion for the immersive world of audiobooks.
Retina UK awards new research funding
Retina UK is delighted to have awarded a new three-year research grant to Prof Majlinda Lako at Newcastle University for a project entitled: To establish AAV.PRPF31 gene augmentation in PRPF31-deficient RPE and photoreceptor cells and assess its efficacy in restoring RPE and photoreceptor function.
e-Newsletter October 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Remember Retina UK in your Will
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
The UK Inherited Retinal Dystrophy Consortium
In 2014 we funded an exciting new collaborative project. The UK Inherited Retinal Dystrophy Consortium (UKIRDC) Project brought together the four largest research groups in the UK specialising in inherited retinal diseases (IRDs).
BBC Lifeline Appeal 2025
During our 50th anniversary year, Retina UK was the focus of a BBC Lifeline Appeal on Sunday 16 November 2025.
FAQs: Luxturna (voretigene neparvovec)
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
ProQR clinical trial for Leber’s Congenital Amourosis (LCA) 10
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.